Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 3
1997 3
1999 2
2000 2
2001 1
2003 2
2004 1
2005 7
2006 1
2007 8
2008 7
2009 1
2015 2
2016 2
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridines as potent and selective SST5 agonists for the treatment of congenital hyperinsulinism.
Zhao J, Wang S, Hee Kim S, Han S, Rico-Bautista E, Sturchler E, Nguyen J, Tan H, Staley C, Karin Kusnetzow A, Betz SF, Johns M, Goulet L, Luo R, Fowler M, Athanacio J, Markison S, Scott Struthers R, Zhu Y. Zhao J, et al. Among authors: markison s. Bioorg Med Chem Lett. 2022 Sep 1;71:128807. doi: 10.1016/j.bmcl.2022.128807. Epub 2022 May 20. Bioorg Med Chem Lett. 2022. PMID: 35605837
Discovery of CRN04894: A Novel Potent Selective MC2R Antagonist.
Kim SH, Han S, Zhao J, Wang S, Kusnetzow AK, Reinhart G, Fowler MA, Markison S, Johns M, Luo R, Struthers RS, Zhu Y, Betz SF. Kim SH, et al. Among authors: markison s. ACS Med Chem Lett. 2024 Mar 19;15(4):478-485. doi: 10.1021/acsmedchemlett.3c00514. eCollection 2024 Apr 11. ACS Med Chem Lett. 2024. PMID: 38628803
Body weight regulation by selective MC4 receptor agonists and antagonists.
Foster AC, Joppa M, Markison S, Gogas KR, Fleck BA, Murphy BJ, Wolff M, Cismowski MJ, Ling N, Goodfellow VS, Chen C, Saunders J, Conlon PJ. Foster AC, et al. Among authors: markison s. Ann N Y Acad Sci. 2003 Jun;994:103-10. doi: 10.1111/j.1749-6632.2003.tb03168.x. Ann N Y Acad Sci. 2003. PMID: 12851304 Review.
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.
Zhang X, Tellew JE, Luo Z, Moorjani M, Lin E, Lanier MC, Chen Y, Williams JP, Saunders J, Lechner SM, Markison S, Joswig T, Petroski R, Piercey J, Kargo W, Malany S, Santos M, Gross RS, Wen J, Jalali K, O'Brien Z, Stotz CE, Crespo MI, Díaz JL, Slee DH. Zhang X, et al. Among authors: markison s. J Med Chem. 2008 Nov 27;51(22):7099-110. doi: 10.1021/jm800851u. J Med Chem. 2008. PMID: 18947224
Toxicological evaluation of two novel bitter modifying flavour compounds: 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-2,4-dione and 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)-5,5-dimethylimidazolidine-2,4-dione.
Karanewsky DS, Arthur AJ, Liu H, Chi B, Ida L, Markison S. Karanewsky DS, et al. Among authors: markison s. Toxicol Rep. 2016 Feb 28;3:310-327. doi: 10.1016/j.toxrep.2016.02.007. eCollection 2016. Toxicol Rep. 2016. PMID: 28959552 Free PMC article.
45 results